CD274 and non-small cell lung carcinoma: In this study, we retrospectively analyzed the treatment outcomes in older patients with NSCLC and with PD-L1 TPS ≥ 50% who received MONO or COMBO as first-line treatment, both of which are recognized as standard first-line treatment options for patients with NSCLC and high PD-L1 TPS.